دورية أكاديمية
Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer.
| العنوان: | Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer. |
|---|---|
| المؤلفون: | Marks MP; Laboratorio de Células Madre/Stem Cells Lab (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490, CP 1428, Ciudad Autónoma de Buenos Aires, Argentina., Giménez CA; Instituto de Ciencias Básicas y Medicina Experimental, Instituto Universitario del Hospital Italiano, Potosí 4265, C1199ACL, Buenos Aires, Argentina.; CASPR Biotech, Buenos Aires, Argentina.; CASPR Biotech, San Francisco, USA., Isaja L; Laboratorio de Investigación Aplicada a Las Neurociencias (LIAN), Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia (FLENI), Ruta 9, Km 53, B1625, Buenos Aires, Escobar, Argentina., Vera MB; Laboratorio de Investigación Aplicada a Las Neurociencias (LIAN), Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia (FLENI), Ruta 9, Km 53, B1625, Buenos Aires, Escobar, Argentina., Borzone FR; Laboratorio de Células Madre/Stem Cells Lab (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490, CP 1428, Ciudad Autónoma de Buenos Aires, Argentina., Pereyra-Bonnet F; Instituto de Ciencias Básicas y Medicina Experimental, Instituto Universitario del Hospital Italiano, Potosí 4265, C1199ACL, Buenos Aires, Argentina.; CASPR Biotech, Buenos Aires, Argentina.; CASPR Biotech, San Francisco, USA., Romorini L; Laboratorio de Investigación Aplicada a Las Neurociencias (LIAN), Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia (FLENI), Ruta 9, Km 53, B1625, Buenos Aires, Escobar, Argentina., Videla-Richardson GA; Laboratorio de Investigación Aplicada a Las Neurociencias (LIAN), Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia (FLENI), Ruta 9, Km 53, B1625, Buenos Aires, Escobar, Argentina., Chasseing NA; Laboratorio de Células Madre/Stem Cells Lab (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490, CP 1428, Ciudad Autónoma de Buenos Aires, Argentina.; Laboratorio de Inmunohematología, (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490, CP 1428, Ciudad Autónoma de Buenos Aires, Argentina., Calvo JC; Laboratorio de Células Madre/Stem Cells Lab (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490, CP 1428, Ciudad Autónoma de Buenos Aires, Argentina., Vellón L; Laboratorio de Células Madre/Stem Cells Lab (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Biología y Medicina Experimental, Vuelta de Obligado 2490, CP 1428, Ciudad Autónoma de Buenos Aires, Argentina. luciano.vellon@ibyme.conicet.gov.ar. |
| المصدر: | Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Feb 28; Vol. 150 (2), pp. 106. Date of Electronic Publication: 2024 Feb 28. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin ; New York : Springer-Verlag. |
| مواضيع طبية MeSH: | Breast Neoplasms*/pathology , Hydroxymethylglutaryl-CoA Reductase Inhibitors*/pharmacology, Humans ; Female ; Hydroxymethylglutaryl CoA Reductases/genetics ; Hydroxymethylglutaryl CoA Reductases/metabolism ; Oxidoreductases ; Cholesterol |
| مستخلص: | Purpose: De novo synthesis of cholesterol and its rate-limiting enzyme, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMGCR), is deregulated in tumors and critical for tumor cell survival and proliferation. However, the role of HMGCR in the induction and maintenance of stem-like states in tumors remains unclear. Methods: A compiled public database from breast cancer (BC) patients was analyzed with the web application SurvExpress. Cell Miner was used for the analysis of HMGCR expression and statin sensitivity of the NCI-60 cell lines panel. A CRISPRon system was used to induce HMGCR overexpression in the luminal BC cell line MCF-7 and a lentiviral pLM-OSKM system for the reprogramming of MCF-7 cells. Comparisons were performed by two-tailed unpaired t-test for two groups and one- or two-way ANOVA. Results: Data from BC patients showed that high expression of several members of the cholesterol synthesis pathway were associated with lower recurrence-free survival, particularly in hormone-receptor-positive BC. In silico and in vitro analysis showed that HMGCR is expressed in several BC cancer cell lines, which exhibit a subtype-dependent response to statins in silico and in vitro. A stem-like phenotype was demonstrated upon HMGCR expression in MCF-7 cells, characterized by expression of the pluripotency markers NANOG, SOX2, increased CD44 +/CD24low/ -, CD133 + populations, and increased mammosphere formation ability. Pluripotent and cancer stem cell lines showed high expression of HMGCR, whereas cell reprogramming of MCF-7 cells did not increase HMGCR expression. Conclusion: HMGCR induces a stem-like phenotype in BC cells of epithelial nature, thus affecting tumor initiation, progression and statin sensitivity. (© 2024. The Author(s).) |
| References: | PLoS One. 2013 Oct 04;8(10):e77281. (PMID: 24124614) Cell Cycle. 2013 Nov 15;12(22):3471-7. (PMID: 24107627) Oncogene. 2021 Dec;40(48):6601-6613. (PMID: 34621019) Cancer Res. 2016 Apr 15;76(8):2063-70. (PMID: 27197250) Genes Dis. 2023 Mar 23;11(2):830-846. (PMID: 37692500) Sci Rep. 2016 Jan 18;6:19435. (PMID: 26777065) Cancer Lett. 2013 Jan 28;328(2):285-96. (PMID: 23063651) Cancer Res. 2011 Jul 1;71(13):4640-52. (PMID: 21712410) RNA. 2008 Oct;14(10):2115-24. (PMID: 18755840) Mol Cancer Res. 2019 Nov;17(11):2318-2330. (PMID: 31420371) Cell Rep. 2019 Jun 25;27(13):3927-3938.e6. (PMID: 31242424) Stem Cells. 2012 Jul;30(7):1327-37. (PMID: 22605458) Cancer Metab. 2013 Nov 07;1(1):20. (PMID: 24279929) Cell Stem Cell. 2015 Sep 3;17(3):260-71. (PMID: 26340526) Biomark Insights. 2015 Jul 29;10(Suppl 1):125-31. (PMID: 26279620) J Immunol Methods. 2009 Aug 15;347(1-2):70-8. (PMID: 19567251) Int J Mol Sci. 2018 Nov 20;19(11):. (PMID: 30463366) Nat Methods. 2013 Oct;10(10):973-6. (PMID: 23892895) Brain Pathol. 2016 Jan;26(1):43-61. (PMID: 25808628) Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15051-6. (PMID: 20696928) Genes Dev. 2013 Mar 15;27(6):654-69. (PMID: 23512659) Genes Dev. 2004 Aug 1;18(15):1875-85. (PMID: 15289459) BMC Clin Pathol. 2015 May 20;15:8. (PMID: 26109908) Sci Rep. 2017 Oct 26;7(1):14123. (PMID: 29075041) Int J Cancer. 2008 Sep 1;123(5):1146-53. (PMID: 18528862) J Immunol. 2006 Jul 1;177(1):651-6. (PMID: 16785563) Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188351. (PMID: 32007596) Cell Cycle. 2013 Sep 15;12(18):3109-24. (PMID: 23974095) Stem Cell Res Ther. 2021 Apr 16;12(1):245. (PMID: 33863385) Breast Cancer Res. 2010;12(5):R68. (PMID: 20813035) J Cell Mol Med. 2018 Apr;22(4):2177-2189. (PMID: 29377583) J Lipid Res. 2009 Oct;50(10):2095-102. (PMID: 19461118) Cell Res. 2013 Oct;23(10):1163-71. (PMID: 23979020) Nat Med. 2011 Mar;17(3):313-9. (PMID: 21386835) Breast Cancer. 2014 Jan;21(1):96-101. (PMID: 22528804) Cancers (Basel). 2023 Sep 29;15(19):. (PMID: 37835481) Am J Cancer Res. 2023 May 15;13(5):2041-2054. (PMID: 37293171) Sci Rep. 2017 Jul 14;7(1):5410. (PMID: 28710496) Am J Physiol Gastrointest Liver Physiol. 2023 Sep 1;325(3):G239-G250. (PMID: 37366601) PLoS One. 2013 Sep 16;8(9):e74250. (PMID: 24066126) Endocr Relat Cancer. 2022 Dec 12;30(1):. (PMID: 36256855) Breast Cancer. 2017 Mar;24(2):326-335. (PMID: 27300169) Stem Cell Res. 2016 Mar;16(2):300-3. (PMID: 27345989) World J Urol. 2013 Apr;31(2):345-50. (PMID: 22407328) Cancer Res. 2012 Jul 15;72(14):3499-511. (PMID: 22802077) Mol Ther. 2018 Jul 5;26(7):1715-1734. (PMID: 29929789) Sci Rep. 2020 Jan 17;10(1):558. (PMID: 31953433) Trends Mol Med. 2012 May;18(5):245-7. (PMID: 22521522) Onco Targets Ther. 2018 Nov 06;11:7873-7881. (PMID: 30464534) Breast Dis. 2023;42(1):73-83. (PMID: 36938720) Cancer Res Treat. 2021 Oct;53(4):1072-1083. (PMID: 33705623) Oncotarget. 2018 Jun 29;9(50):29304-29315. (PMID: 30034619) Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12759-64. (PMID: 19549847) Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):40-5. (PMID: 20018687) ACS Appl Bio Mater. 2020 Jul 20;3(7):4474-4485. (PMID: 35025446) Pharmacol Rep. 2019 Jun;71(3):535-544. (PMID: 31026757) Cancer Res. 2018 Sep 1;78(17):4803-4808. (PMID: 30120211) Sci Rep. 2023 Feb 15;13(1):2710. (PMID: 36792625) Toxicol Pathol. 2015 Apr;43(3):400-10. (PMID: 25341428) Sci Rep. 2015 Dec 03;5:17454. (PMID: 26632252) Gene Ther. 2016 Jun;23(6):543-7. (PMID: 27052801) |
| معلومات مُعتمدة: | PIP300, 2014-2016, Argentina National Research Council |
| فهرسة مساهمة: | Keywords: Breast cancer; Cancer stem cells; HMGCR; Metabolic reprogramming |
| المشرفين على المادة: | 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) EC 1.1.1.- (Hydroxymethylglutaryl CoA Reductases) EC 1.- (Oxidoreductases) 97C5T2UQ7J (Cholesterol) |
| تواريخ الأحداث: | Date Created: 20240228 Date Completed: 20240301 Latest Revision: 20240324 |
| رمز التحديث: | 20240324 |
| مُعرف محوري في PubMed: | PMC10902018 |
| DOI: | 10.1007/s00432-024-05607-7 |
| PMID: | 38418798 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-1335 |
|---|---|
| DOI: | 10.1007/s00432-024-05607-7 |